Bicara Therapeutics Inc. Common Stock (BCAX) annual balance sheet — 4-year assets, liabilities & equity history
| Total Current Assets | 544.91M | 422.05M | 502.53M | 231.07M | 4.98M |
| Cash & Short-Term Investments | 539.75M | 414.8M | 489.71M | 230.44M | 4.16M |
| Cash Only | 323.46M | 96.69M | 489.71M | 230.44M | 4.16M |
| Short-Term Investments | 216.29M | 318.12M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 5.16M | 7.25M | 12.82M | 100K | 68K |
| Total Non-Current Assets | 8.68M | 8.94M | 66.66M | 2.91M | 1.72M |
| Property, Plant & Equipment | 1.77M | 2.03M | 845K | 815K | 636K |
| Fixed Asset Turnover | 0.00x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 117.42M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 6.91M | 6.91M | 6.62M | 2.09M | 1.08M |
| Total Assets | 553.6M | 430.99M | 569.2M | 233.98M | 6.7M |
| Asset Turnover | 0.00x | - | - | - | - |
| Asset Growth % | 89.79% | -24.28% | 143.26% | 3390.71% | - |
| Total Current Liabilities | 39.34M | 28.95M | 17.99M | 15.09M | 23.9M |
| Accounts Payable | 6.19M | 5.51M | 4.51M | 3.19M | 5.14M |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 1.14M | 1.12M | 607K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 32.01M | 22.32M | 9.79M | 0 | 0 |
| Current Ratio | 13.85x | 14.58x | 27.93x | 15.32x | 0.21x |
| Quick Ratio | 13.85x | 14.58x | 27.93x | 15.32x | 0.21x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 301K | 593K | 59.33M | 389K | 85K |
| Long-Term Debt | 301K | 593K | 0 | 0 | 0 |
| Capital Lease Obligations | 1.16M | 0 | 131K | 372K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 59.2M | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 17K | 85K |
| Total Liabilities | 39.64M | 29.54M | 77.32M | 15.47M | 23.98M |
| Total Debt | 1.44M | 1.71M | 738K | 657K | 0 |
| Net Debt | -322.02M | -94.97M | -488.97M | -229.78M | -4.16M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x | - |
| Debt / EBITDA | -0.01x | - | - | - | - |
| Net Debt / EBITDA | 1.85x | - | - | - | - |
| Interest Coverage | - | - | - | - | -336.89x |
| Total Equity | 513.96M | 401.45M | 491.88M | 218.51M | -17.28M |
| Equity Growth % | 321.65% | -18.38% | 125.11% | 1364.66% | - |
| Book Value per Share | 8.46 | 7.34 | 9.04 | 4.22 | -0.33 |
| Total Shareholders' Equity | 513.96M | 401.45M | 491.88M | 218.51M | -17.28M |
| Common Stock | 8K | 0 | 7K | 2K | 2K |
| Retained Earnings | -415.18M | 0 | -221.02M | -153.02M | -101.04M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -243K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying BCAX stock.
As of 2025, Bicara Therapeutics Inc. Common Stock (BCAX) had total assets of $431.0M including $422.1M in current assets.
Bicara Therapeutics Inc. Common Stock (BCAX) carries total debt of $1.7M, offset by $414.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Bicara Therapeutics Inc. Common Stock (BCAX) has total shareholders' equity (book value) of $401.5M ($7.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Bicara Therapeutics Inc. Common Stock (BCAX) reported a current ratio of 14.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.